Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > FDA guides on how AA can be converted to full approval.

<< Previous

Bullboard Posts

Next >>

Comment by Kswdeluxon Mar 26, 2023 7:44am

184 Views

Post# 35361062

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA guides on how AA can be converted to full approval.

I don't know the answer to this...

In an AA scenario where the product is then sale-able, is the product sold throughout the trial at the actual product sales end point price?

Or, is it sold at a discounted price throughout the trial?

My thought is, with AA will we only know the discounted sale price, or will we know the actual final endpoint sale price?

Knowing the actual final endpoint sale price for ONC per patient would immediately redefine market cap potential significantly more accurately.

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities